Thursday, 1 September, 2022 - 16:01
Lixa targets global biotech market
Perth startup Lixa is on the path to commercialising medical research from the University of Western Australia after gaining backing from tech hub CERI and raising $2.2 million.
Maud Eijkenboom
Co-Founder, Chief Executive, Director / Lixa
Dr Maud Eijkenboom has vast experience in developing drugs, biologicals and medical devices for multinational and ASX-listed companies, universities and startups. She has accelerated technology development programs through industry accepted discovery programs, feasibility studies, mechanism of action, proof of concept studies and clinical programs.
Dr Eijkenboom is the inventor on five patents.
She holds a PhD in Neuroscience from the University of Groningen, and a Master of Science in Comparative and Physiological Psychology from the Radboud University.
